Robert Minor, MD
Interventional Cardiology · Billings, MTNPI 1740209261
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 78.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $18,053 and has fallen 98.1% since, to $337 in 2025. Among interventional cardiology clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $376.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$36K
- Surmodics, Inc.$9K
- Abbott$244
- Novartis$202
- E.r. Squibb & Sons, L.L.C.$131
- Terumo Medical Corporation$113
- plus $344 from 10 others
Across 1 payment — averaging $281.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$281
What the payments were for
- Consulting fees$12,46927%
- Speaking & faculty fees$26,72558%
- Travel & lodging$3,3747%
- Food & beverage$3,3507%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 76 | $35,809 |
| Surmodics, Inc. | 4 | $9,075 |
| Abbott | 5 | $244 |
| Novartis | 12 | $202 |
| E.r. Squibb & Sons, L.L.C. | 7 | $131 |
| Terumo Medical Corporation | 1 | $113 |
| Siemens Medical Solutions USA, Inc. | 2 | $88 |
| Boston Scientific | 3 | $54 |
| Shockwave Medical, Inc | 3 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Johnson & Johnson | 2 | $28 |
| Medline Industries LP | 1 | $23 |
| Amgen | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$21,285
- Sublime 014 Rx PTA Balloon Dilatation Catheter$18,000
- Sublime Radial Access 018 RX PTA Dilatation Catheter$9,000
- Sublime Microcatheter, 014, 65cm, Straight$9,000
- Sublime Microcatheter, 014, 65cm, Angle$9,000
- SpiderFX$4,500
- IN.PACT Admiral$3,616
- IN.PACT AV$1,600
- Resolute$1,554
- TurboHawk$319
- Navicross$113
- HERCULINK ELITE$113
How this compares
$45,918 in reported general payments places this provider in the 90th percentile of 22 interventional cardiology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 222 | $141,905 |
| EliquisApixaban | 83 | $73,422 |
| EntrestoSacubitril/Valsartan | 69 | $60,645 |
| JardianceEmpagliflozin | 15 | $18,278 |
| BrilintaTicagrelor | 28 | $11,946 |
| Atorvastatin Calcium | 296 | $2,942 |
| Metoprolol Succinate | 213 | $2,828 |
| Pantoprazole Sodium | 231 | $2,557 |
| Losartan Potassium | 282 | $2,447 |
| ClopidogrelClopidogrel Bisulfate | 206 | $2,351 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 94 | $1,809 |
| Flecainide Acetate | 20 | $1,132 |
| Midodrine Hcl | 21 | $1,075 |
| Potassium Chloride | 67 | $1,053 |
| Rosuvastatin Calcium | 138 | $1,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $28 | $141,905222 claims |
| NovartisEntresto | $202 | $60,64569 claims |
| Boehringer IngelheimJardiance | $17 | $18,27815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 interventional cardiology providers in Montana.
Other interventional cardiology in Billings
- Claudia Lama von BuchwaldBillings$29K
- Per SommerBillings$27K
- Robert TerryBillings$12K
- Ronald HenckelBillings$6K
- Shunsuke AoiBillings$3K
- Brian RahBillings$805
- Cindy TomBillings$80
- Steven GoldbergGreat Falls$134K
- Daniel SpoonMissoula$58K
- Michael EisenhauerGreat Falls$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.